Factors Associated with Bleeding After ESD

On the basis of a comprehensive literature review, including a prior systematic review,20 (link) and clinical relevance, we identified that the following variables were potentially associated with bleeding after ESD: sex, comorbidities (ischaemic heart disease, liver cirrhosis and chronic kidney disease (CKD) with haemodialysis), AT therapy (aspirin, P2Y12RA, cilostazol, warfarin and DOAC), the tumour characteristics (multiple tumours, lower-third in tumour location, tumour size >30 mm, undifferentiated type, submucosal invasion ≥500 µm from the muscularis mucosa (SM2) and ulceration) and procedure (ESD procedure time >120 min and SLE). We also selected characteristics that may influence bleeding, including age (≥75 years), piecemeal resection and mild/no endoscopic gastric atrophy according to the Kimura and Takemoto classification.21 (link) With regard to the AT agents, the variables for the interruption of AT agents, heparin bridging and replacement of APAs were included in the model because of their possible influence on bleeding.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Hatta W., Tsuji Y., Yoshio T., Kakushima N., Hoteya S., Doyama H., Nagami Y., Hikichi T., Kobayashi M., Morita Y., Sumiyoshi T., Iguchi M., Tomida H., Inoue T., Koike T., Mikami T., Hasatani K., Nishikawa J., Matsumura T., Nebiki H., Nakamatsu D., Ohnita K., Suzuki H., Ueyama H., Hayashi Y., Sugimoto M., Yamaguchi S., Michida T., Yada T., Asahina Y., Narasaka T., Kuribasyashi S., Kiyotoki S., Mabe K., Nakamura T., Nakaya N., Fujishiro M, & Masamune A. (2020). Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score. Gut, 70(3), 476-484.

Publication 2020

Aspirin Chronic kidney disease Cilostazol Endoscopic Gastric atrophy Haemodialysis Heparin Ischaemic heart disease Liver cirrhosis Muscularis mucosa Therapy Tumour Tumour location Ulceration Warfarin

Corresponding Organization : Nagoya University

Other organizations : Tohoku University, The University of Tokyo, Japanese Foundation For Cancer Research, Shizuoka Cancer Center, Toranomon Hospital, Ishikawa Prefectural Central Hospital, Osaka City University, Fukushima Medical University Hospital, Jikei University School of Medicine, Kobe University, Tonan Hospital, Wakayama Medical University, Ehime University, Osaka City General Hospital, Hirosaki University Hospital, Fukui Prefectural Hospital, Yamaguchi University, Chiba University, Toyonaka Municipal Hospital, Nagasaki University Hospital, National Cancer Centre Japan, Juntendo University, Osaka University, Tokyo Medical University Hospital, Shiga University of Medical Science Hospital, Kansai Rosai Hospital, Saitama Medical University, National Center for Global Health and Medicine, Kanazawa University Hospital, University of Tsukuba, Gunma University, Shuto General Hospital, Hakodate National Hospital, National Hospital Organization, Tohoku Medical Megabank Organization, Saitama Prefectural University

Top 5 similar protocols

Protocol cited in 3 other protocols

Variable analysis

independent variables

Comorbidities (ischaemic heart disease, liver cirrhosis and chronic kidney disease (CKD) with haemodialysis)
AT therapy (aspirin, P2Y12RA, cilostazol, warfarin and DOAC)
Tumour characteristics (multiple tumours, lower-third in tumour location, tumour size >30 mm, undifferentiated type, submucosal invasion ≥500 µm from the muscularis mucosa (SM2) and ulceration)
Procedure (ESD procedure time >120 min and SLE)
Age (≥75 years)
Piecemeal resection
Mild/no endoscopic gastric atrophy according to the Kimura and Takemoto classification
Interruption of AT agents
Heparin bridging
Replacement of APAs

dependent variables

Bleeding after ESD

control variables

None explicitly mentioned

controls

None explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!